サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ペプチド抗生物質の市場規模、シェア、動向分析レポート：製品タイプ別、疾患別、投与経路別（経口、注射、局所）、流通チャネル別、地域別、セグメント別予測、2022年～2030年
市場調査レポート
商品コード
1114073

ペプチド抗生物質の市場規模、シェア、動向分析レポート：製品タイプ別、疾患別、投与経路別（経口、注射、局所）、流通チャネル別、地域別、セグメント別予測、2022年～2030年

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Product Type, By Disease, By Route Of Administration (Oral, Injectable, Topical), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
ペプチド抗生物質の市場規模、シェア、動向分析レポート：製品タイプ別、疾患別、投与経路別（経口、注射、局所）、流通チャネル別、地域別、セグメント別予測、2022年～2030年
出版日: 2022年07月19日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ペプチド抗生物質市場の成長と動向

グランドビューリサーチ社の最新レポートによると、ペプチド抗生物質の世界市場規模は2030年までに66億米ドルに達すると予測されています。

同市場は2022年から2030年にかけてCAGR4.6%で拡大すると予測されています。この市場は、ペプチド抗生物質分野の研究開発活動の増加や、多くの医薬品承認などの要因によって、成長機会を目の当たりにすることが期待されます。また、抗菌剤耐性菌の増加や従来の抗生物質による副作用の可能性も、予測期間中に市場を牽引するものと思われます。

また、がんやその他の感染症が増加していることも、予測期間中の成長を促進すると考えられています。例えば、CDCによると、米国は2019年に599,589人の死亡とともに1,752,735人の新たながん患者を報告しました。人口10万人あたり、439人の新規症例が見つかり、146人ががんが原因で死亡しています。さらに、Globocan 2020によると、英国は2020年に457,960人の新規患者が発生し、179,648人が死亡しています。悪性腫瘍の種類としては、乳がん、前立腺がん、非ホジキンリンパ腫が多くなっています。

ペプチド系抗生物質には、非ホジキンリンパ腫、ホジキンリンパ腫、ある種の皮膚悪性腫瘍などの治療に使用されるものがあります。Globocan 2020によると、非ホジキンリンパ腫の患者数は5,443,352人、ホジキンリンパ腫の患者数は83,087人となっています。また、医師による推奨により、様々な既存製品の効率的な使用により、より高い収益が期待されます。例えば、注射用ブレオマイシンUSPは、Streptomyces verticillusから分離された細胞毒性糖ペプチド抗生物質の混合物で、精巣がん、扁平上皮がん、さまざまな種類のリンパ腫の治療に使用されています。

さらに、進行中の製品承認や、パートナーシップ、提携、製品の発売、拡大など、市場関係者が実施する戦略的イニシアティブは、予測期間中の市場成長を促進すると予想されます。例えば、2021年7月、AbbVie Incは、出生時からの小児患者における急性細菌性皮膚・皮膚構造感染症の治療薬としてDALVANCEを米国FDAが承認したことを発表しました。さらに、2020年7月、Sandoz International GmbHは、Cubicinの後発品であるDaptomycin injection 500 mgを、複雑な皮膚および皮膚構造感染症および数種の血流感染症の成人患者の治療薬として米国市場に導入すると発表しました。

ペプチド抗生物質市場レポートハイライト

2021年、非リボソーム合成ペプチドセグメントは、その高い需要に起因して市場を独占した

小売薬局セグメントが最も高いシェアを占め、予測期間中もその優位性を維持すると思われる

アジア太平洋地域は、感染症の流行や患者数の増加などの要因から、予測期間中に最も高いCAGRを記録すると予想される

北米は、ペプチド抗生物質製品への高い需要、主要な市場プレイヤーの存在、地域内の研究活動の増加により、2021年の市場全体を支配しています。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 調査手法
  • 情報調達
    • 購入したデータベース：
    • GVRの内部データベース
    • 二次情報
    • 1次調査
    • 1次調査内容
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析
      • アプローチ1：コモディティフローアプローチ
  • 二次情報一覧
  • 略語一覧
  • 目的

第2章 エグゼクティブサマリー

  • 市場概要

第3章 ペプチド抗生物質市場の変数、動向、範囲

  • 市場力学
    • 市場促進要因分析
      • 病院や診療所でのペプチド抗生物質の採用の増加
      • 微生物耐性の発生率の増加
    • 市場制約分析
      • ペプチド抗生物質に関連する副作用
  • 浸透と成長の見通しのマッピング
  • ビジネス環境分析ツール
    • SWOT分析;要因別（政治と法律、経済と技術）
    • ポーターのファイブフォース分析
    • 業界分析- アンソフマトリックス
  • 価格分析
  • 規制シナリオ

第4章 規制および政治勢力

  • 主要な市場参加者別最近の動向と影響分析
    • Heat map analysis
  • 会社の分類
    • イノベーター
    • 市場のリーダー
  • ベンダー情勢
    • 主要なディストリビューターとチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2021年
  • 公開会社
    • 企業の市況分析
      • 市場の差別化要因
  • プライベートカンパニー
    • 主要新興企業一覧
  • 主要取引と戦略的提携分析
    • 新製品の発売
    • 買収
    • 拡張
    • ライセンシングとパートナーシップ

第5章 ペプチド抗生物質市場-セグメント分析、製品タイプ、2018年から2030年（百万米ドル）

  • 製品タイプの市場シェア分析、2021年および2030年（USD Million）
  • セグメントダッシュボード
  • 市場規模と予測、トレンド分析、2018年から2030年（100万米ドル）
    • リボソーム合成ペプチド抗生物質
    • 非リボソーム合成ペプチド抗生物質

第6章 ペプチド抗生物質市場-セグメント分析、疾患別、2018年から2030年（百万米ドル）

  • 疾患市場シェア分析、2021年および2030年（100万米ドル）
  • セグメントダッシュボード
  • 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
    • 皮膚感染症
    • HABP/VABP
    • 血流感染症
    • その他

第7章 ペプチド抗生物質市場-セグメント分析、投与経路別、2018年から2030年（百万米ドル）

  • 投与経路の市場シェア分析、2021年および2030年（100万米ドル）
  • セグメントダッシュボード
  • 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
    • オーラル
    • 注射可能
    • 話題の
    • その他

第8章 ペプチド抗生物質市場-セグメント分析、流通チャネル別、2018年から2030年（百万米ドル）

  • 流通チャネルの市場シェア分析、2021年および2030年（100万米ドル）
  • セグメントダッシュボード
  • 市場規模と予測、トレンド分析、2018年から2030年（USD Million）
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第9章 ペプチド抗生物質市場-セグメント分析、地域別、2018年から2030年（百万米ドル）

  • 地域市場シェア分析、2021年および2030年（100万米ドル）
  • 地域市場ダッシュボード
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • スペイン
    • フランス
    • イタリア
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東とアフリカ
    • 南アフリカ
    • アラブ首長国連邦
    • サウジアラビア

第10章 競争力とベンダー情勢

  • 参加者の分類
    • イノベーター
    • 市場のリーダー
  • 戦略マッピング
    • この市場でプレーヤーが選択した主要な戦略には、次のものがあります。
      • 新製品の発売
      • 取得
      • 拡張
      • 契約、コラボレーション、パートナーシップ
      • その他（再編、売却、市場浸透）：
  • 戦略的枠組み
    • 主要企業の市場シェア分析、2021年
  • 企業プロファイル
    • Pfizer Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Sandoz International GmbH
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • GSK Group of Companies.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • AbbVie Inc
      • 会社概要
      • 財務実績
      • 製品パイプライン
      • 戦略的イニシアチブ
    • Merck &Co., Inc
      • 会社概要
      • 財務実績
      • 製品パイプライン
      • 戦略的イニシアチブ
    • Xellia PHARMACEUTICALS
      • 会社概要
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Theravance Biopharma
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
    • AuroMedics Pharma LLC
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 5 North America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 6 North America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 10 US Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 US Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 14 Canada Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 19 Europe Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Europe Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 U.K. Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 22 U.K. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 23 U.K. Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 U.K. Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Germany Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 27 Germany Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Germany Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 30 France Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 31 France Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 France Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Spain Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 35 Spain Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Spain Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Italy Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 39 Italy Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Italy Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Japan Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 47 Japan Peptide Antibiotics Market, By Disease 2018 - 2030 (USD Million)
  • Table 48 Japan Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Japan Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 China Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 51 China Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 52 China Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 China Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 India Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 55 India Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 56 India Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 India Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Korea Peptide Antibiotics Market, By Product Type2018 - 2030 (USD Million)
  • Table 59 South Korea Peptide Antibiotics Market, By Disease 2018 - 2030 (USD Million)
  • Table 60 South Korea Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 South Korea Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Australia Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 64 Australia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Latin America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 69 Latin America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Latin America Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 Brazil Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Peptide Antibiotics Market, By Disease 2018 - 2030 (USD Million)
  • Table 73 Brazil Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Brazil Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Mexico Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 77 Mexico Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Mexico Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 81 Argentina Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Argentina Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 Middle East & Africa Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 South Africa Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 90 South Africa Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 South Africa Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 96 UAE Peptide Antibiotics Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 97 UAE Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 98 UAE Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 99 UAE Peptide Antibiotics Market, Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Peptide antibiotics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Peptide antibiotics market snapshot
  • Fig. 10 Peptide antibiotics market driver impact
  • Fig. 11 Peptide antibiotics market restraint impact
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Ansoff matrix
  • Fig. 16 Peptide antibiotics market: Product type outlook and key takeaways
  • Fig. 17 Peptide antibiotics market: Product type movement analysis
  • Fig. 18 Product type segment dashboard
  • Fig. 19 Ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non-ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Peptide antibiotics market: Disease outlook and key takeaways
  • Fig. 22 Peptide antibiotics market: Disease movement analysis
  • Fig. 23 Disease segment dashboard
  • Fig. 24 Skin infections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 HABP/VABP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Blood stream infections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Peptide antibiotics market: Route of Administration outlook and key takeaways
  • Fig. 29 Peptide antibiotics market: Route of Administration movement analysis
  • Fig. 30 Route of Administration segment dashboard
  • Fig. 31 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Peptide antibiotics market: Distribution channel outlook and key takeaways
  • Fig. 36 Peptide antibiotics market: Distribution channel movement analysis
  • Fig. 37 Distribution channel segment dashboard
  • Fig. 38 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Peptide antibiotics market: regional outlook and key takeaways
  • Fig. 42 Regional outlook, 2021 & 2030 (USD Million)
  • Fig. 43 Regional market dashboard
  • Fig. 44 North America
  • Fig. 45 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 U.S.
  • Fig. 47 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Canada
  • Fig. 49 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Germany
  • Fig. 53 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 U.K.
  • Fig. 55 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Spain
  • Fig. 57 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 France
  • Fig. 59 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Italy
  • Fig. 61 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Asia Pacific
  • Fig. 63 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Japan
  • Fig. 65 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 China
  • Fig. 67 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 India
  • Fig. 69 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea
  • Fig. 71 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Australia
  • Fig. 73 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Mexico
  • Fig. 79 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Argentina
  • Fig. 81 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Middle East & Africa
  • Fig. 83 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa
  • Fig. 85 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 UAE
  • Fig. 87 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia
  • Fig. 89 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Participant categorization
  • Fig. 91 Strategy mapping
  • Fig. 92 Strategic framework
  • Fig. 93 Company market share analysis
目次
Product Code: GVR-4-68039-958-4

Peptide Antibiotics Market Growth & Trends:

The global peptide antibiotics market size is expected to reach USD 6.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.6% from 2022 to 2030. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin's lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin's lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin's lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

Peptide Antibiotics Market Report Highlights:

  • In 2021, the non-ribosomal synthesized peptide segment dominated the market owing to their higher demand
  • The retail pharmacy segment held the highest share and is likely to maintain its dominance throughout the forecast period
  • Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
  • North America dominated the overall market in 2021 due to the higher demand for peptide antibiotics products, presence of leading market players, and increased research activities within the region

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: commodity flow approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
    • 1.9.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Peptide Antibiotics Market Variables, Trends & Scope

  • 3.1 Market Dynamics
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing adoption of peptide antibiotics in hospitals and clinics
      • 3.1.1.2 Increasing incidences of microbial resistance
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Side-effects associated with peptide antibiotics
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Business Environment Analysis Tools
    • 3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    • 3.3.2 Porter's Five Forces Analysis
    • 3.3.3 Industry Analysis - Ansoff Matrix
  • 3.4 Pricing Analysis
  • 3.5 Regulatory Scenario

Chapter 4 Regulatory & Political Forces

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 4.1.1 Heat map analysis
  • 4.2 Company Categorization
    • 4.2.1 Innovators
    • 4.2.2 Market Leaders
  • 4.3 Vendor Landscape
    • 4.3.1 List of key distributors and channel partners
    • 4.3.2 Key customers
    • 4.3.3 Key company market share analysis, 2021
  • 4.4 Public Companies
    • 4.4.1 Company market position analysis
      • 4.4.1.1 Market differentiators
  • 4.5 Private Companies
    • 4.5.1 List of key emerging companies
  • 4.6 Major Deals and Strategic Alliances Analysis
    • 4.6.1 New product launch
    • 4.6.2 Acquisitions
    • 4.6.3 Expansion
    • 4.6.4 Licensing and partnerships

Chapter 5 Peptide Antibiotics Market - Segment Analysis, By Product Type, 2018 - 2030 (USD Million)

  • 5.1 Product Type Market Share Analysis, 2021 & 2030 (USD Million)
  • 5.2 Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
    • 5.3.1 Ribosomal Synthesized Peptide Antibiotics
      • 5.3.1.1 Ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2 Non-Ribosomal Synthesized Peptide Antibiotics
      • 5.3.2.1 Non-ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Peptide Antibiotics Market - Segment Analysis, By Disease, 2018 - 2030 (USD Million)

  • 6.1 Disease Market Share Analysis, 2021 & 2030 (USD Million)
  • 6.2 Segment Dashboard
  • 6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
    • 6.3.1 Skin Infections
      • 6.3.1.1 Skin infections market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.2 HABP/VABP
      • 6.3.2.1 HABP/VABP market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.3 Blood Stream Infection
      • 6.3.3.1 Blood stream infection market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.4 Others
      • 6.3.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Peptide Antibiotics Market - Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)

  • 7.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
  • 7.2 Segment Dashboard
  • 7.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
    • 7.3.1 Oral
      • 7.3.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.2 Injectable
      • 7.3.2.1 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.3 Topical
      • 7.3.3.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.4 Others
      • 7.3.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Peptide Antibiotics Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 8.1 Distribution Channel Market Share Analysis, 2021 & 2030 (USD Million)
  • 8.2 Segment Dashboard
  • 8.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
    • 8.3.1 Hospital Pharmacies
      • 8.3.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.3.2 Retail Pharmacies
      • 8.3.2.1 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.3.3 Online Pharmacies
      • 8.3.3.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Peptide Antibiotics Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 9.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
  • 9.2 Regional Market Dashboard
  • 9.3 North America
    • 9.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.3.2 U.S.
      • 9.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.3.3 Canada
      • 9.3.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 9.4 Europe
    • 9.4.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.4.2 Germany
      • 9.4.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.4.3 U.K.
      • 9.4.3.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.4.4 Spain
      • 9.4.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.4.5 France
      • 9.4.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.4.6 Italy
      • 9.4.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 9.5 Asia Pacific
    • 9.5.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.5.2 Japan
      • 9.5.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.5.3 China
      • 9.5.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.5.4 India
      • 9.5.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.5.5 South Korea
      • 9.5.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.5.6 Australia
      • 9.5.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 9.6 Latin America
    • 9.6.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.6.2 Brazil
      • 9.6.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.6.3 Mexico
      • 9.6.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.6.4 Argentina
      • 9.6.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 9.7 Middle East & Africa
    • 9.7.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.7.2 South Africa
      • 9.7.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.7.3 UAE
      • 9.7.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 9.7.4 Saudi Arabia
      • 9.7.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Competitive & Vendor Landscape

  • 10.1 Participant Categorization
    • 10.1.1 Innovators
    • 10.1.2 Market Leaders
  • 10.2 Strategy Mapping
    • 10.2.1 Key Strategies Chosen by Players in this Market Include:
      • 10.2.1.1 Launch of new products
      • 10.2.1.2 Acquisition
      • 10.2.1.3 Expansion
      • 10.2.1.4 Agreements, collaborations, partnerships
      • 10.2.1.5 Others (realignment, divestment, market penetration):
  • 10.3 Strategic Framework
    • 10.3.1 Key Company Market Share Analysis, 2021
  • 10.4 Company Profiles
    • 10.4.1 Pfizer Inc.
      • 10.4.1.1 Company overview
      • 10.4.1.2 Financial performance
      • 10.4.1.3 Product benchmarking
      • 10.4.1.4 Strategic initiatives
    • 10.4.2 Sandoz International GmbH
      • 10.4.2.1 Company overview
      • 10.4.2.2 Financial performance
      • 10.4.2.3 Product benchmarking
      • 10.4.2.4 Strategic initiatives
    • 10.4.3 GSK Group of Companies.
      • 10.4.3.1 Company overview
      • 10.4.3.2 Financial performance
      • 10.4.3.3 Product benchmarking
      • 10.4.3.4 Strategic initiatives
    • 10.4.4 AbbVie Inc
      • 10.4.4.1 Company overview
      • 10.4.4.2 Financial performance
      • 10.4.4.3 Product pipeline
      • 10.4.4.4 Strategic initiatives
    • 10.4.5 Merck & Co., Inc
      • 10.4.5.1 Company overview
      • 10.4.5.2 Financial performance
      • 10.4.5.3 Product pipeline
      • 10.4.5.4 Strategic initiatives
    • 10.4.6 Xellia PHARMACEUTICALS
      • 10.4.6.1 Company overview
      • 10.4.6.2 Product benchmarking
      • 10.4.6.3 Strategic initiatives
    • 10.4.7 Theravance Biopharma
      • 10.4.7.1 Company overview
      • 10.4.7.2 Financial performance
      • 10.4.7.3 Product benchmarking
    • 10.4.8 AuroMedics Pharma LLC
      • 10.4.8.1 Company overview
      • 10.4.8.2 Financial performance
      • 10.4.8.3 Product benchmarking
      • 10.4.8.4 Strategic initiatives